ArticleJournal of orthopaedic case reports2026
Photobiomodulation Therapy Modulates Inflammatory and Cartilage Biomarkers in Patients with Knee Osteoarthritis: A Pilot Case Series.
Article in Journal of orthopaedic case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Knee osteoarthritis (KOA) is a common degenerative joint disease characterized by pain, inflammation, and progressive cartilage degradation. Current treatments often provide limited relief, encouraging the exploration of adjuvant, non-invasive modalities such as photobiomodulation therapy (PBMT). Although PBMT has demonstrated analgesic and anti-inflammatory potential, its biochemical effects in KOA remain underexplored. Case Report: This pilot clinical investigation included 30 patients with clinically and radiographically confirmed KOA, allocated into two groups (PBMT, n = 15; placebo, n = 15). All participants received identical treatment protocols, with the placebo group undergoing sham irradiation. Synovial fluid and blood samples were collected before and after the intervention to assess inflammatory and cartilage metabolism biomarkers, including interleukins (IL-1, IL-6, and IL-10), tumor necrosis factor-alpha (TNF-α), matrix metalloproteinases (MMP-3 and MMP-13), collagen type II C-telopeptide (CTX-II), and prostaglandin E2 (PGE2). Results: PBMT produced significant biochemical and clinical modulation compared with placebo. In serum, PBMT reduced IL-1, IL-6, TNF-α, and PGE2 levels while increasing IL-10 concentrations. In synovial fluid, significant reductions were observed in MMP-3, MMP-13, CTX-II, IL-1, IL-6, and TNF-α, accompanied by increased IL-10 levels. Clinically, PBMT participants reported substantial pain reduction and improved joint mobility.The observed reductions in inflammatory cytokines and cartilage degradation biomarkers indicate that PBMT exerts both systemic and intra-articular modulatory effects. The increase in IL-10 suggests activation of anti-inflammatory regulatory pathways, which may contribute to the clinical improvements observed. These findings reinforce the hypothesis that PBMT acts not only through symptomatic relief but also through modulation of disease-related biochemical mechanisms. Conclusion: PBMT demonstrates beneficial local and systemic effects on inflammatory and cartilage degradation pathways in KOA, supporting its potential as an adjunctive therapeutic strategy. Larger controlled clinical trials are warranted to confirm these findings and establish standardized treatment parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.